Global Proteomics | Next-Generation Proteomics | Large-Scale Proteomics
Contact us Helpdesk

Transforming life sciences with next-generation proteomics

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.

OUR STORY

Close in on your research and clinical development goals with Large-Scale Discovery Proteomics

Biognosys turned proteomics into a true discovery technology with unprecedented precision, depth, and scale. Our industry-leading proteome coverage and high-throughput facility enable simultaneous quantification of thousands of proteins across thousands of samples. Through our proprietary technology and advanced data analytics capabilities we generate actionable insights for R&D and clinical research.

LARGE-SCALE PROTEOMICS

Our Solutions

Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.

OUR SERVICES

We offer a complete suite of software solutions for any mass spectrometry proteomics application in industry or academic life sciences research.

OUR SOFTWARE

Our kits and reagents for sample preparation, quantification and quality control empower researchers to apply cutting-edge proteomics in-house.

OUR KITS

Latest News & Stories

News
SpectroMine 3 is here! Unearth the Full Potential of DDA Proteomics

SpectroMine 3 comes with many novel and enhanced features for unsurpassed performance for DDA[...]

READ MORE
News
Biognosys Launches Next-Generation Blood Biomarker Discovery Solution

The new and improved service will offer unprecedented depth, precision, and throughput, quantifying up to 3,000 proteins in plasma or[...]

READ MORE
News
Indivumed and Biognosys Extend Strategic Partnership

The Partnership Will Combine Each Company’s Capabilities in Omics Research to Provide Biopharma Customers with Immunopeptidomics Insights for Drug[...]

READ MORE
News
Biognosys to Present Major Scientific and Technological Advances at the ASMS 2021 Mass Spectrometry Conference

Highlights include workflow innovations in Plasma Proteomics and Immunopeptidomics, and enhanced Proteomics data analysis with[...]

READ MORE
News
Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine

Cancer Scout combines Genomics, Proteomics, and Pathology data through Artificial Intelligence into a "digital biopsy" that supports early, accurate cancer diagnosis and[...]

READ MORE
News
Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

The new and improved workflow will offer unprecedented depth and quantitative precision, identifying up to 3,000 plasma proteins   October 5th, 2021 – SCHLIEREN, (Zurich,[...]

READ MORE
News
Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-Generation Proteomics

The Agreement Aims to Accelerate the Continuum of Diagnostic Biomarker Discovery through to Assay Development and Clinical[...]

READ MORE
News
Biognosys Announces New Release of Spectronaut™

  15 June 2021 – SCHLIEREN (Zürich – Switzerland) The leading software solution for DIA proteomics is compatible with MS instruments from all major vendors, including[...]

READ MORE
Resource - Launch Pages
Spectronaut™ 15: Expand Biological Insights with DIA Proteomics

Spectronaut 15 comes with many novel and enhanced features for the most complete and versatile quantitative proteomics[...]

READ MORE
News
Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Kristina Beeler as Chief Business[...]

READ MORE
News
Biognosys Announces Strategic Agreement with Siemens Healthineers

The Agreement Aims to Accelerate the Continuum of Diagnostic Biomarker Discovery through to Assay Development and Clinical[...]

READ MORE

Join Email List

    Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

    Join the Biognosys email list to receive news and exclusive content.

    Join Email List

      Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.